Market Closed -
Hong Kong S.E.
04:08:03 2024-05-23 am EDT
|
5-day change
|
1st Jan Change
|
0.99
HKD
|
-2.94%
|
|
+2.06%
|
-50.50%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
9,682
|
5,321
|
3,070
|
1,227
|
619.6
|
-
|
-
|
Enterprise Value (EV)
1 |
6,573
|
3,061
|
1,338
|
240.1
|
619.6
|
619.6
|
619.6
|
P/E ratio
|
-3.31
x
|
-7.61
x
|
-4.69
x
|
-1.93
x
|
-1.25
x
|
-1.52
x
|
-1.89
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
185
x
|
19.2
x
|
18.2
x
|
4.44
x
|
2.01
x
|
1.1
x
|
EV / Revenue
|
-
|
185
x
|
19.2
x
|
18.2
x
|
4.44
x
|
2.01
x
|
1.1
x
|
EV / EBITDA
|
-19.3
x
|
-8.77
x
|
-3.55
x
|
-1.82
x
|
-1.14
x
|
-1.37
x
|
-1.65
x
|
EV / FCF
|
-26,980,554
x
|
-9,157,733
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
3.19
x
|
2.23
x
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
671,181
|
665,683
|
674,889
|
674,889
|
674,889
|
-
|
-
|
Reference price
2 |
14.43
|
7.993
|
4.548
|
1.818
|
0.9181
|
0.9181
|
0.9181
|
Announcement Date
|
3/25/21
|
3/18/22
|
3/28/23
|
3/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
28.77
|
160.1
|
67.3
|
139.7
|
308.7
|
565.4
|
EBITDA
1 |
-501.6
|
-606.7
|
-865.1
|
-674.4
|
-542.8
|
-452.2
|
-375.6
|
EBIT
1 |
-502.3
|
-618.2
|
-878.9
|
-691.5
|
-561
|
-471.1
|
-396.1
|
Operating Margin
|
-
|
-2,148.99%
|
-548.87%
|
-1,027.34%
|
-401.62%
|
-152.63%
|
-70.06%
|
Earnings before Tax (EBT)
1 |
-
|
-655.5
|
-601.5
|
-581.2
|
-475.4
|
-392.9
|
-319.8
|
Net income
1 |
-2,929
|
-655.5
|
-601.5
|
-581.2
|
-475.4
|
-392.9
|
-319.8
|
Net margin
|
-
|
-2,278.6%
|
-375.61%
|
-863.51%
|
-340.39%
|
-127.28%
|
-56.56%
|
EPS
2 |
-4.364
|
-1.050
|
-0.9700
|
-0.9400
|
-0.7353
|
-0.6057
|
-0.4847
|
Free Cash Flow
|
-358.9
|
-581
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-2,019.67%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/25/21
|
3/18/22
|
3/28/23
|
3/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S2
|
2021 S1
|
2021 S2
|
2022 S1
|
2022 S2
|
2023 S1
|
2023 S2
|
2024 S1
|
2024 S2
|
---|
Net sales
1 |
-
|
-
|
28.77
|
53.96
|
106.2
|
72.02
|
-4.711
|
60.01
|
77.88
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-214
|
-404.3
|
-
|
-568.5
|
-339.3
|
-352.2
|
-241
|
-243.7
|
Operating Margin
|
-
|
-
|
-1,405.22%
|
-
|
-535.44%
|
-471.14%
|
7,475.12%
|
-401.64%
|
-312.94%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-
|
-
|
-
|
-
|
-0.7400
|
-0.3600
|
-0.5800
|
-0.3400
|
-0.3500
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/25/21
|
8/20/21
|
3/18/22
|
8/31/22
|
3/28/23
|
9/27/23
|
3/22/24
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
3,110
|
2,260
|
1,732
|
987
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-359
|
-581
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-236%
|
-24.1%
|
-29.3%
|
-40.6%
|
-58.3%
|
-63.8%
|
-61%
|
ROA (Net income/ Total Assets)
|
-148%
|
-22.8%
|
-25.6%
|
-
|
-
|
-
|
-
|
Assets
1 |
1,977
|
2,876
|
2,350
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
4.530
|
3.580
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-0.8900
|
-0.9300
|
-
|
-
|
-
|
-
|
Capex
|
-
|
23.4
|
99.4
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
81.3%
|
62.06%
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/25/21
|
3/18/22
|
3/28/23
|
3/22/24
|
-
|
-
|
-
|
Last Close Price
0.9181
CNY Average target price
1.666
CNY Spread / Average Target +81.51% Consensus |
1st Jan change
|
Capi.
|
---|
| -50.50% | 88.18M | | +10.79% | 115B | | +11.65% | 106B | | -6.20% | 24.69B | | -2.33% | 21.97B | | -6.03% | 19.27B | | -13.41% | 17.56B | | -40.50% | 17.32B | | +6.64% | 14.03B | | +31.84% | 12.13B |
Bio Therapeutic Drugs
|